ArticleAntimicrobial agents and chemotherapy2010
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- Repurposing drugs to advance the treatment of Buruli ulcer.Antimicrobial agents and chemotherapy · 2025Article
- Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.PLoS neglected tropical diseases · 2024Article
- Unlocking Opportunities forACS infectious diseases · 2024Review
- Bacteria-Based Living Probes: Preparation and the Applications in Bioimaging and Diagnosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Overview: Development of Drugs Against Mycobacterium ulcerans.Methods in molecular biology (Clifton, N.J.) · 2022Article
- In Vitro Assessment of Drug Activity Against Mycobacterium ulcerans.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance forActa pharmaceutica Sinica. B · 2021Article
- Evaluation of Nucleoside Analogs as Antimicrobials Targeting Unique Enzymes inPathogens (Basel, Switzerland) · 2020Article
- Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach.Antimicrobial agents and chemotherapy · 2020Article
- In Vivo Imaging of BioluminescentThe American journal of tropical medicine and hygiene · 2019Article
- The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.Nature communications · 2019Article
- Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.PLoS neglected tropical diseases · 2019Article
- Establishment and Validation of Galleria mellonella as a Novel Model Organism To Study Mycobacterium abscessus Infection, Pathogenesis, and Treatment.Antimicrobial agents and chemotherapy · 2018Article
- Mutation EthAInfection and drug resistance · 2018Article
- In Silico Prediction of Antibiotic Resistance inThe American journal of tropical medicine and hygiene · 2017Article
- Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2017Article
- A Cassette Containing Thiostrepton, Gentamicin Resistance Genes, andFrontiers in microbiology · 2017Article
- Animal Models for Tuberculosis in Translational and Precision Medicine.Frontiers in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Mycobacterium ulcerans causes Buruli ulcer, an emerging infectious disease for which antimicrobial therapy has only recently proven to be beneficial. The discovery and development of new drugs against M. ulcerans are severely impeded by its very slow growth. Recombinant bioluminescent strains have proven useful in drug development for other mycobacterial infections, but the ability of such strains to discriminate bacteriostatic from bactericidal activity has not been well demonstrated. We engineered recombinant M. ulcerans strains to express luxAB from Vibrio harveyi. In drug susceptibility tests employing a wide range of antimicrobial agents and concentrations, the relative light unit (RLU) count measured in real time was a reliable surrogate marker for CFU counts available 3 months later, indicating utility for the rapid determination of drug susceptibility and discrimination of bacteriostatic and bactericidal effects. A second important finding of this study is that the addition of subinhibitory concentrations of the ATP-binding cassette transporter inhibitor reserpine increases the susceptibility of M. ulcerans to tetracycline and erythromycin, indicating that drug efflux may explain at least part of the intrinsic resistance of M. ulcerans to these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.